Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Feed not found.
Contact us
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st fl.), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
D-U-N-S: 362071645
-
- + 7 985 908 58 18 9am-6pm GMT+3
-
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- Novartis Tafinlar + Mekinist Approved by FDA for Pediatric Patients with BRAF V600E Low-Grade Glioma
- FDA Approves Expanded Indication for Telix’s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy
- FDA Approves Daybue (trofinetide) for the Treatment of Rett Syndrome
- FDA Approves Zavzpret (zavegepant) Nasal Spray for the Acute Treatment of Migraine
- FDA Broadens Indication for Verzenio (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
News and press releases
- EMA Management Board: highlights of March 2023 meeting, MB, 17/03/2023
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 - 16 March 2023, PRAC, 17/03/2023
- Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 December 2022, CVMP, 09/12/2022
- Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 February 2023, CVMP, 17/02/2023
Drugs.com - Clinical Trials
- Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham TORONTO, March 21, 2023....
- New Yale study evaluates PAXLOVID's use in Long COVID recovery NEW HAVEN, Conn., March 21,...
- First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia CAPE CANAVERAL, Fla., March...
- Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials TOKYO & BASKING RIDGE,...